NCT03720873

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

An Multicenter,Phase II Trial of EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: Fujian Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A single arm study: EGFR-TKIs Combine With Anlotinib as First-line Treatment in patients with EGFR-mutant non-small-cell lung cancer (NSCLC).

Detailed description

This trial investigated the efficacy and safety of EGFR-TKIs Combine With Anlotinib as First-line Treatment in patients with EGFR-mutant NSCLC.

Conditions

• EGFR Gene Mutation

Interventions

Type	Name	Description
DRUG	erlotinib or gefitinib or icotinib	Patients will be treated with erlotinib 150mgQD or gefitinib250mgQD or icotinib 125 mg TID
DRUG	Anlotinib	Patients will be treated with Anlotinib 12mg po d1-14 Q21d

Timeline

• Start date: 2018-10-01
• Primary completion: 2021-06-01
• Completion: 2022-09-01
• First posted: 2018-10-25
• Last updated: 2018-10-25

Locations

1 site across 1 country: China